91ÊÓƵרÇø

¾ÝÁ˽⣬µçÊÓ¾çµÄ³öÆ··½°üÀ¨Æó¶ìÓ°ÊÓ¡¢ÈþÌåÓîÖæ¡¢ÁéºÓÎÄ»¯µÈ£¬ÆäÖÐÈþÌåÓîÖæͬʱ»¹ÊǵİæȨ·½¡£2018Ä꣬ÓÎ×åÍøÂ紴ʼÈËÁÖÆæÖ÷µ¼ÁËÊÕ¹º°æȨµÄÏà¹ØÊÂÏ³ÉΪΨһ°æȨ·½£¬²¢×¨ÃųÉÁ¢ÁËÈþÌåÓîÖ棬À´½øÐбõ±ÊµÄÏîÄ¿ÍƽøºÍÂäµØ¹¤×÷¡£

2024Äê12ÔÂ24ÈÕ£¬ºÝ×¥·¢Õ¹µÚÒ»ÒªÎñ£¬×ÛºÏʵÁ¦ÂõÉÏÐĄ̂½×£»

37´óµ«ÈËÎÄÒÕÊõÈ«ÎÄÔĶÁ³å37´óµ«ÈËÎÄÒÕÊõ³å×îÐÂÕ½ڳåË«...

ËýµÄͯÄêÉú»î¼òµ¥¶ø³äʵ²»ÊǺÍСÅóÓÑÃÇÍæË£±ãÊÇÔÚ¼ÒÀï¿´µçÊÓÈ»¶øκЦ²¢²»ºÍÆÕͨµÄСÅóÓÑÒ»Ñùϲ»¶¿´¶¯»­Æ¬Ëýϲ»¶ºÍ¸¸Ç×Ò»Æð¿´ÐÂÎÅ

ûÓÐÁËÅóÓѲ»¿ÉÅ£¬ÎÒÄþ¿É¶À´¦£¬Ò²±ÈÌÍÐÄÌÍ·ÎÌÍ¿Õ×Ô¼ºÇ¿¡£ÈçºÎÇø·Ö·ÇµäÐÍCMLÓëÆäËû¹ÇËèÔöÖ³ÐÔÖ×ÁöÔ­´´2020-09-12 17:53¡¤Ò½ÂöͨѪҺ¿Æ×÷ÕߣºÀ¶¾¨Ïþ»¢±¾ÎÄΪ×÷ÕßÊÚȨҽÂöͨ·¢²¼£¬Î´¾­ÊÚȨÇëÎðתÔØ¡£·ÇµäÐÍÂýÐÔËèϵ°×Ѫ²¡(aCML)£¬BCR-ABL1(£­)£¬ÊÇÒ»ÖÖº±¼ûµÄѪҺ¶ñÐÔÖ×Áö£¬ÊôÓÚWHO¹ÇËèÖ×Áö·ÖÀàÖеĹÇËèÔöÉúÒì³£/¹ÇËèÔöÖ³ÐÔÖ×Áö(MDS/MPN)¡£aCML×î³õ±»ÃüÃûΪ¡°·ÇµäÐÍ¡±ÐÎʽµÄÂýÐÔËèϵ°×Ѫ²¡(CML)£¬¼¸Ê®ÄêÀ´aCMLµÄÕï¶Ï±ê×¼·¢ÉúÁËÏÔÖø±ä»¯¡£È»¶ø£¬aCMLµÄÕï¶Ïȱ·¦ÌØÕ÷ÐÔ£¬¶ÔÆä·Ö×Ó»ùÒòͼÆ×µÄÈÕÒæÁ˽âÓÐÖúÓÚÇø·ÖaCMLÓëÆäËûMDS/MPNºÍMPNs£¬ÒÔ±ãÔçÆÚÆô¶¯ÖÎÁƺ͸ÄÉÆÔ¤ºó¡£aCMLµÄÁÙ´²ºÍÐÎ̬±íÐÍaCML»¼Õß±íÏÖ³ö¹ÇËèÔöÉúÌØÕ÷£¬°üÀ¨°×ϸ°ûÔö¶àºÍÆ¢Ö״󣬿ɰéÓÐƶѪºÍѪС°å¼õÉÙ¡£WBC¼ÆÊý¡Ý13¡Á109/L¡£ÍâÖÜѪÖдæÔÚÖÁÉÙ10%µÄδ³ÉÊìÁ£Ï¸°û£¨°üÀ¨ÔçÓ×Á£Ï¸°û¡¢ÖÐÓ×Á£Ï¸°ûºÍÍíÓ×Á£Ï¸°û£©£¬ÒÔÖضÈÁ£Ï¸°ûÉú³ÉÕÏ°­ÎªÌØÕ÷¡£²»´æÔÚµ¥ºËϸ°ûÔö¶à£¨ÍâÖÜѪµ¥ºËϸ°û<ѪҺ°×ϸ°ûµÄ10%£¬ÑªÒº¼ÆÊý< 1¡Á109/L£©ÍâÖÜѪÖеÄÊȼîÐÔÁ£Ï¸°û< 2%¡£¹ÇËèºÍÍâÖÜѪÖÐԭʼϸ°û£¨°üÀ¨Ó×µ¥ºËϸ°û£©< 20%¡£ÐÎ̬ѧÉÏ£¬aCMLÍâÖÜѪ±íÏÖΪÑÏÖØÁ£Ï¸°ûÒìÐÍÔöÉú¡£ÌØÕ÷ÐÔ±íÏÖ°üÀ¨ÖÐÐÔÁ£Ï¸°ûµÄȾɫÖʹý¶È¾Û¼¯ÒÔ¼°ºË·ÖÁÑÏóÒì³££¬ÈçºËµÍ·ÖÒ¶(¼ÙPelger-HuetºË)»ò¶à·ÖÒ¶¡£°û½¬¿É³Ê¿ÅÁ£¼õÉÙÉõÖÁÒì³£Ôö´ó¡£¹ÇËèϸ°û¹ý¶à£¬ÒÔÁ£Ï¸°ûΪÖ÷£¬³ÊÃ÷ÏÔÒìÐÍÔöÉú¡£°ëÊýÒÔÉϲ¡ÀýÓкìϵ·¢Óý²»Á¼ºÍÒ»¶¨³Ì¶ÈµÄ¾ÞºËϸ°û·¢Óý²»Á¼¡£´ËÍ⣬¿É¼û²»Í¬³Ì¶ÈµÄÍøÓ²µ°°×ÏËάÔö¼Ó¡£WHO 2016ÄêÌá³öµÄaCMLÒÔ¼°¾ßÓÐÏàËÆÌØÕ÷µÄËèϵÖ×ÁöÕï¶Ï±ê×¼×ܽá¼ûÏÂ±í¡£×¢£ºaCML£¬·ÇµäÐÍÂýÐÔËèÐÔ°×Ѫ²¡£»BM£¬¹ÇË裻CMML£¬ÂýÐÔÁ£µ¥ºËϸ°û°×Ѫ²¡£»ET£¬Ô­·¢ÐÔѪС°åÔö¶àÖ¢£»MDS/MPN-RS-T£¬¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö°é»·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àÖ¢£»MDS/MPN-U£¬¹ÇËèÔöÉúÒì³£/¹ÇËèÔöÉúÐÔÖ×Áö£¬²»¿É·ÖÀࣻPV£¬ÕæÐÔºìϸ°ûÔö¶àÖ¢£»PB£¬ÍâÖÜѪ¡£aCMLµÄϸ°ûÒÅ´«Ñ§ÌØÕ÷¾¡¹Ü¸ù¾Ý¶¨Ò壬aCMLȱ·¦·Ñ³ÇȾɫÌå¼°BCR-ABL1ÖØÅÅ£¬µ«Ô¼Ò»°ëµÄaCML²¡Àý´æÔÚϸ°ûÒÅ´«Ñ§»û±ä£¬°üÀ¨8ÈýÌå¡¢YȾɫÌåȱʧ¡¢20ºÅȾɫÌ峤±Û²¿·Öȱʧ(20q-)¡¢17ºÅµÈ±ÛȾɫÌå¡¢Éæ¼°12¡¢13¡¢14¡¢17ºÅȾɫÌåµÄȱʧºÍ¸´ÔÓºËÐÍ¡£È»¶øÕâЩϸ°ûÒÅ´«Ñ§Òì³£¾ù·ÇaCMLËùÌØÓУ¬ÇÒÏ൱¶àµÄ²¡Àý£¨¸ß´ï80%£©¿É¾ßÓÐÕý³£µÄºËÐÍ¡£aCMLµÄ¸´·¢ÐÔ»ùÒòÍ»±äaCMLÖÐ×î³£¼ûµÄÍ»±ä»ùÒòÊÇASXL1¡¢NRAS¡¢SETBP1¡¢SRSF2ºÍTET2¡£×î½üÑо¿±íÃ÷£¬69%µÄaCML²¡ÀýÔÚ±í¹ÛÒÅ´«ÐÞÊλùÒòTET2¡¢IDH1/2¡¢DNMT3A¡¢EZH2ºÍ/»òASXL1ÖÐЯ´øÖÁÉÙÒ»ÖÖÍ»±ä¡£Í¼1×ܽáÁËaCMLÖÐ×î³£¼ûµÄÍ»±ä¡£ÈçºÎÕï¶ÏaCMLÕï¶ÏaCMLÓ¦»ùÓÚʶ±ðÆäÌØÕ÷ÐÔµÄÐÎ̬ѧ¡¢ÊµÑéÊÒºÍÒÅ´«Ñ§ÌØÕ÷£¬Åųý¾ßÓÐÃ÷È·ÒÅ´«Ñ§¸Ä±äµÄÆäËûËèϵ¶ñÐÔÖ×Áö¡£³õ²½¼ì²éÓ¦²àÖØÓÚÅųýBCR-ABL1Èںϣ¬¸ù¾Ý¶¨Ò壬CML±ØÈ»´æÔÚBCR-ABL1Èںϣ¬¶øaCMLÖÐÎÞ´ËÏÖÏó¡£»¹Ó¦ÅųýÆäËû²¡ÀíÐÔ»ùÒòÍ»±ä£¬ÈçPDGFRA¡¢PDGFRB¡¢FGFR1£¬»òPCM1-JAK2Èںϡ£¼øÓÚÕâЩÖØÅÅ¿ÉÄÜ´æÔÚÒÅ´«Ñ§ÒþÃØ£¬³ýÁ˺ËÐÍ·ÖÎö£¬ÔÚÈ·¶¨aCMLÕï¶Ï֮ǰ£¬Ó¦¿¼ÂÇFISH¼ì²â»òRNA-²âÐòÀ´ÅųýÉÏÊöÇé¿ö¡£PDGFRBÖØÅŵÄËèϵÖ×Áö»¼Õ߿ɱíÏÖΪMDS/MPNÑù±íÐÍ£¬ÐÎ̬ѧÌØÕ÷ÓëaCMLÏàËÆ¡£ÏÖÒÑÒâʶµ½£¬PDGFRBÖØÅŵÄËèϵÖ×Áö¾ßÓзdz£¹ã·ºµÄ±íÐÍ£¬²¢²»¾ÖÏÞÓÚ°éÊÈËáÐÔÁ£Ï¸°ûÔö¶àÌØÕ÷µÄCMML¡£Ê¶±ðÖØÅÅ£¨ÈçPDGFRB/PDGFRA£©ÖÁ¹ØÖØÒª£¬ÒòΪÓëaCMLÏà±È£¬¾ßÓÐÕâÀàÌØÕ÷µÄ¼²²¡¶ÔÀÒ°±ËἤøÒÖÖƼÁ£¨ÒÁÂíÌæÄᣩµÄÃô¸ÐÐԸߣ¬Ô¤ºó½ÏºÃ¡£Çø·ÖaCMLÓëijЩBCR-ABL1£¨-£©µÄMPNs £¨CNL£¬Ô­·¢ÐÔ¹ÇËèÏËά»¯[PMF]£©ºÍMDS/MPN£¨CMMLºÍMDS/MPN-U£©¾ßÓÐÌôÕ½ÐÔ¡£MPN¼ÈÍùÊ·¿ÉÅųýaCMLµÄÕï¶Ï¡£¹ÇËè»î¼ì·¢ÏÖµäÐ͵ÄMPNÐÎ̬ѧ½á¹û£¨ÓÈÆäÊÇÔÚûÓÐÏÔÖøÁ£Ï¸°û·¢Óý²»Á¼µÄÇé¿öÏ£©ºÍMPNÏà¹ØÍ»±ä£¨ÔÚJAK2¡¢CALR»òMPLÖУ©Ê±£¬²»ÇãÏòaCML£¬ÌáʾPMF¡¢ÕæÐÔºìϸ°ûÔö¶àÖ¢(PV)»òÔ­·¢ÐÔѪС°åÔö¶àÖ¢(ET)¡£ÌáʾÐÔµÄÍ»±äÌØÕ÷£¨ÈçSETBP1/ETNK1Í»±ä£©ÇÒ¾ßÓзûºÏÕï¶Ï±ê×¼µÄÌØÕ÷ÓÐÖúÓÚ֤ʵaCML¡£ÍâÖÜѪÖе¥ºËϸ°ûµÄ°Ù·Ö±ÈÊÇÇø·ÖaCMLºÍCMMLµÄÖØÒªÌØÕ÷£¬ÔÚaCMLÖÐʼÖÕµÍÓÚ10%£¨ºÜÉÙ>2%£©¡£Ï¸°û»¯Ñ§È¾É«£¬Èç·ÇÌØÒìÐÔõ¥Ã¸(NSE)ÓÐÖúÓÚÔÚÒÉÄѲ¡ÀýÖмì²âµ¥ºËϸ°û¡£ÁíÒ»¸ö¸üÖ÷¹ÛµÄÐÎ̬ѧÇø±ðÊÇaCML´æÔÚ¸üÑÏÖصÄÁ£Ï¸°û·¢Óý²»Á¼£¬¾¡¹Üȱ·¦ÆÀ¹À·¢Óý²»Á¼ÑÏÖس̶ȵľßÌåÖ¸ÄÏ¡£ÐèÒª½øÐÐÌúȾɫÒÔÅųý°éÓл·ÐÎÌúÁ£Ó×ϸ°ûºÍѪС°åÔö¶àµÄMDS/MPN-RS-T¡£ÔÚÒÔÔöÖ³ÌØÕ÷ΪÖ÷£¬ÇÒÒÔÖÐÐÔÁ£Ï¸°ûΪÖ÷µÄ»¼ÕßÖУ¬CSF3RÍ»±äӦǿÁÒÌáʾCNL¡£Çø·ÖaCMLÓëMDS/MPN-U½ÏΪÀ§ÄÑ¡£aCML»¼ÕßµÄÖÐλWBC¼ÆÊýÏÔÖøÉý¸ß£¬µ«·Ç¾ø¶ÔÌØÕ÷¡£³ÖÐøÐÔµ¥ºËϸ°ûÔö¶àÌáʾCMML¡£TET2+SRSF2Í»±ä¶ÔCMML¾ßÓÐÏà¶ÔÌØÒìÐÔ£¬¾¡¹ÜÁ½ÕßÔÚaCMLÖоù¿É¼û¡£Ò»ÖÖеÄaCMLÕï¶ÏÁ÷³ÌС½áÓÉÓÚ·¢²¡Âʵ͡¢Õï¶Ï±ê×¼²»¶Ï¸üкÍȱ·¦·Ö×ÓÒÅ´«Ñ§µÄÀí½â£¬·ÇµäÐÍÂýÐÔËèϵ°×Ѫ²¡Ò»Ö±ÊÇÒ»ÖÖÄÑÒÔÕï¶ÏµÄMDS/MPN¡£Ëæ×ŶԻùÒò×é´óÊý¾ÝµÄ²»¶ÏÍÚ¾ò£¬ÒÑ·¢ÏÖSETBP1ºÍETNK1µÄ·´¸´Í»±ä¶ÔaCMLÓÐÌáʾ×÷Ó㬿ÉÒÔ½áºÏʵÑéÊÒºÍÐÎ̬ѧ½á¹ûÀ´Çø·ÖaCMLºÍÆäËû·Ñ³ÇÒõÐÔ¹ÇËèÔöÖ³ÐÔÖ×Áö¡£È»¶øÍ»±äµÄͬʱ·¢ÉúÊÇ·ñ»á¸Ä±äaCMLµÄ¼²²¡±íÐͺÍÖÎÁÆ·´Ó¦Éв»Ã÷È·¡£²Î¿¼ÎÄÏ×£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.